About Thrombotax

Targeting the TSP-1:CD47 axis may represent a promising antithrombotic strategy. MEDyC researchers engineered the first ever antagonist being selective for TSP-1:CD47 interaction, namely TAX2 peptide (patent WO2013007933A1, worldwide rights licensed to Apmonia Therapeutics), exhibiting an exciting pharmacological profile for controlling platelet activation in prothrombotic diseases.

The objective of THROMBOTAX is to validate TAX2 as an innovative and beneficial option of high added value in the therapeutic landscape of acute ischemic stroke.

The main research & development axes consist in:

• Providing knowledge on how the TSP-1/CD47 axis is engaged in thrombotic cardiovascular diseases
• Providing deep insights into the therapeutic value of TSP-1 for patients with thrombotic diseases using advanced preclinical models
• Demonstrating the efficacy of TAX2 treatment in this context
• Providing an optimization of TAX2 as a drug-candidate by developing a dedicated formulation
• Developing, in the longer term, a new antithrombotic drug candidate with the advantage of inducing fewer side effects than current therapies.